ADMA Biologics, Inc. Secures Up to $6 Million Term Loan Commitment to Advance Phase III Study  
1/7/2013 10:00:27 AM

HACKENSACK, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc.(ADMA), a late-stage biotechnology company focused on developing specialty immune globulin therapeutics and the commercialization of human plasma, announced it has entered into a $6 million term loan commitment with Hercules Technology Growth Capital, Inc., (Hercules: NYSE: HTGC).